|
Gene: STK11IP |
Gene summary for STK11IP |
Gene summary. |
Gene information | Species | Human | Gene symbol | STK11IP | Gene ID | 114790 |
Gene name | serine/threonine kinase 11 interacting protein | |
Gene Alias | LIP1 | |
Cytomap | 2q35 | |
Gene Type | protein-coding | GO ID | GO:0008104 | UniProtAcc | C9JQV3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
114790 | STK11IP | LZE24T | Human | Esophagus | ESCC | 8.56e-05 | 1.40e-01 | 0.0596 |
114790 | STK11IP | P2T-E | Human | Esophagus | ESCC | 1.56e-11 | 1.22e-01 | 0.1177 |
114790 | STK11IP | P8T-E | Human | Esophagus | ESCC | 2.61e-07 | 9.85e-02 | 0.0889 |
114790 | STK11IP | P10T-E | Human | Esophagus | ESCC | 6.74e-03 | 1.13e-01 | 0.116 |
114790 | STK11IP | P11T-E | Human | Esophagus | ESCC | 1.23e-02 | 2.06e-01 | 0.1426 |
114790 | STK11IP | P15T-E | Human | Esophagus | ESCC | 1.27e-09 | 1.18e-01 | 0.1149 |
114790 | STK11IP | P16T-E | Human | Esophagus | ESCC | 2.44e-07 | 1.59e-01 | 0.1153 |
114790 | STK11IP | P20T-E | Human | Esophagus | ESCC | 1.15e-03 | 9.78e-02 | 0.1124 |
114790 | STK11IP | P21T-E | Human | Esophagus | ESCC | 2.10e-05 | 1.37e-01 | 0.1617 |
114790 | STK11IP | P22T-E | Human | Esophagus | ESCC | 1.67e-02 | 5.09e-02 | 0.1236 |
114790 | STK11IP | P24T-E | Human | Esophagus | ESCC | 4.48e-03 | 6.87e-02 | 0.1287 |
114790 | STK11IP | P26T-E | Human | Esophagus | ESCC | 1.24e-03 | 8.75e-02 | 0.1276 |
114790 | STK11IP | P27T-E | Human | Esophagus | ESCC | 1.52e-06 | 1.30e-01 | 0.1055 |
114790 | STK11IP | P28T-E | Human | Esophagus | ESCC | 4.29e-03 | 1.15e-01 | 0.1149 |
114790 | STK11IP | P30T-E | Human | Esophagus | ESCC | 1.13e-02 | 1.72e-01 | 0.137 |
114790 | STK11IP | P32T-E | Human | Esophagus | ESCC | 3.19e-05 | 8.26e-02 | 0.1666 |
114790 | STK11IP | P37T-E | Human | Esophagus | ESCC | 1.36e-05 | 1.02e-01 | 0.1371 |
114790 | STK11IP | P40T-E | Human | Esophagus | ESCC | 2.09e-04 | 1.25e-01 | 0.109 |
114790 | STK11IP | P47T-E | Human | Esophagus | ESCC | 1.22e-02 | 5.03e-02 | 0.1067 |
114790 | STK11IP | P48T-E | Human | Esophagus | ESCC | 4.24e-03 | 6.53e-02 | 0.0959 |
Page: 1 2 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ESCC: Esophageal squamous cell carcinoma | |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
STK11IP | SNV | Missense_Mutation | rs757266751 | c.2378N>A | p.Arg793Gln | p.R793Q | protein_coding | deleterious(0.01) | probably_damaging(0.963) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
STK11IP | SNV | Missense_Mutation | rs776082847 | c.3229N>T | p.Arg1077Trp | p.R1077W | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-F1-A448-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | capecitabine | CR | |
STK11IP | SNV | Missense_Mutation | rs372789253 | c.1181N>T | p.Thr394Met | p.T394M | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-FP-A4BE-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fluorouracil | CR | |
STK11IP | SNV | Missense_Mutation | novel | c.2276A>G | p.Lys759Arg | p.K759R | protein_coding | tolerated(0.23) | benign(0.025) | TCGA-VQ-A8DT-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | fluorouracil | PD | |
STK11IP | SNV | Missense_Mutation | rs763330999 | c.1154N>A | p.Arg385Gln | p.R385Q | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | ||
STK11IP | SNV | Missense_Mutation | rs376215443 | c.3248N>T | p.Ala1083Val | p.A1083V | protein_coding | tolerated(0.25) | benign(0.03) | TCGA-VQ-A8PP-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD | |
STK11IP | insertion | Frame_Shift_Ins | novel | c.1529_1530insTTTCC | p.Glu511PhefsTer82 | p.E511Ffs*82 | protein_coding | TCGA-FY-A4B0-01 | Thyroid | thyroid carcinoma | Male | >=65 | I/II | Hormone Therapy | synthroid | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |